ADMA Biologics vs Krystal Biotech
ADMA and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADMA and KRYS compare
Krystal Biotech is the larger company, worth 3.1 times as much as ADMA Biologics ($9.0B against $3.0B).
On earnings, ADMA Biologics is cheaper: it trades at 17.2× trailing earnings, against 41.5× for Krystal Biotech.
Krystal Biotech grew revenue faster over the last twelve months (26.0% versus 6.3% for ADMA Biologics).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 47.9% compared with 35.1% at ADMA Biologics.
ADMA Biologics scores higher on the StockData Score (16 against 11 for Krystal Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADMA | KRYS |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $9.0B |
| Share price | $13.24 | $305.68 |
| Change, 1 year | −17.4% | 50.6% |
| Change, 5 years | 765% | 484% |
| Beta (5Y) | 0.64 | 0.84 |
| Employees | 647 | 295 |
| StockData Score | ||
| Total score | 16 (better) | 11 |
| Valuation score | 5 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.2× (better) | 41.5× |
| P/S | 5.7× (better) | 19.2× |
| P/B | 6.8× | 6.3× (better) |
| EV/EBITDA | 12.2× (better) | 35.8× |
| P/FCF | 22.3× (better) | 29.2× |
| FCF yield | 4.5% (better) | 3.4% |
| Fair value | $21.15 | $215.10 |
| Margin of safety | 37.4% (better) | −42.1% |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 26.0% (better) |
| Revenue growth, 5Y average | 64.6% | – |
| Net income growth (TTM) | −12.9% | 13.2% (better) |
| EPS growth (TTM) | −9.4% | 10.5% (better) |
| Profitability | ||
| Gross margin | 68.5% | – |
| Operating margin | 46.5% | 48.4% (better) |
| Net margin | 35.1% | 47.9% (better) |
| FCF margin | 25.6% | 66.0% (better) |
| Return on equity | 41.9% (better) | 17.5% |
| Return on invested capital | 39.4% | 42.6% (better) |
| Financial health | ||
| Debt / equity | 0.45 (better) | 0.00 |
| Net debt / EBITDA | 0.29 | – |
| Interest coverage | 22.8× | – |
| Current ratio | 6.04 | 7.89 (better) |
| Altman Z-score | 8.58 | 37.76 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | 6.4% | – |
| Shareholder yield | 6.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 91.8% | 102% |
| Held by insiders | 3.0% | 17.2% |
| Insider net buying, 12 months | −$2.5M (better) | −$105M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 8.3% | 12.4% |
Go deeper
- ADMA stock overview
- ADMA income statement
- ADMA valuation and score
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.